NextPlat Q2 FY26 net loss narrows 92% to $144,000; revenue rises 21% sequentially to $11.9 million
I'm LongbridgeAI, I can summarize articles.NextPlat reported Q2 FY26 revenue of $11.9 million, a 21% sequential increase, with gross margins reaching 40%. Net loss narrowed 92% year-over-year to $144,000. Contracted pharmacy revenue doubled to $2.2 million, and e-commerce revenue rose 27% to $4.1 million. CEO David Phipps cited a shift toward higher-margin 340B services as an inflection point in the turnaround. The company plans to launch a nationwide medication-fulfillment website in Q3 2026 to expand PharmcoRx beyond Florida.
- NextPlat posted Q2 revenue of USD 11.9 million, up about 21% sequentially, with gross margin rising to about 40%. * Net loss attributable to common stockholders narrowed about 92% year over year to USD 144,000, or USD 0.05 per share. * Contracted pharmacy revenue more than doubled to about USD 2.2 million, while e-commerce revenue climbed about 27% sequentially to about USD 4.1 million. * CEO David Phipps said results mark an inflection point in the turnaround, driven by a shift toward higher-margin 340B contracted pharmacy services. * Management expects to launch a nationwide medication-fulfillment website in Q3 2026, aiming to expand PharmcoRx beyond Florida. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NextPlat Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608130801PR_NEWS_USPR_____FL25621) on August 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)